Novartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42.

Novartis immunologist describes the excitement of discovering a promising new immuno-oncology (IO) target in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

New Global Head of Cardiovascular and Metabolic Diseases Research looks to apply new tools to address tough challenges.

A complex protein module keeps the liver’s biochemical factory running smoothly and at capacity.

Ask Alan Frohman how he found out that he had glaucoma, and he'll quickly tell you that there were no warning signs.

Marc Pelletier traveled from Cambridge, MA to Shanghai, China, to launch new lines of research for the treatment of cancers that are common in China.

For all too many people living with heart failure, hospitalizations are a recurring part of life, affecting the lives of both patients and their caregivers.